Shidlovski/iStock via Getty Images Based on interim mid-stage data for its gene therapy candidate, Ixo-vec, Adverum Biotechnologies ( NASDAQ: ADVM ) announced Wednesday that the one-time therapy caused 76% of patients with wet age-related macular degeneration (wet AMD) to remain injection-free at Week 26. The findings were based on the company’s ongoing LUNA Phase 2 trial, which tested two doses of Ixo-vec with a corticosteroid prophylactic regimen in patients with wet AMD, the leading cause of blindness in people older than 65 years. Citing a Feb.
14 data cut based on 58 patients, the company said 76% and 83% of patients who received Ixo-vec at 6E10 and 2E11 doses were injection-free at Week 26, respectively. Findings support “our selection of the 6E10 dose with a local prophylactic regimen for Phase 3 pivotal studies,” CEO Laurent Fischer remarked. While Ixo-vec was well tolerated across both doses with no treatment-related adverse events, the company said there were two discontinuations due to adverse events unrelated to the study drug.
Adverum ( ADVM ) expects to announce nine-month data from LUNA in Q4 2024, along with an update on the drug’s pivotal trial design. More on Adverum Biotechnologies Adverum Biotechnologies a new buy at H.C.
Wainwright on wet AMD gene therapy Seeking Alpha’s Quant Rating on Adverum Biotechnologies Historical earnings data for Adverum Biotechnologies Financial information for Adverum Biotechnologies.
